Actively Recruiting
Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease
Led by Changi General Hospital · Updated on 2026-04-22
40
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital. Eligible patients with Stage 3 or 4 CKD will be assigned preferencebased to either a plant-based diet intervention (intake of at least 50% protein from plant sources) with regular dietitian counselling and follow up, or a control group receiving dietitian counselling for general CKD dietary advice without information on percentage of plant-based foods. Six monthly assessments will include estimated glomerular filtration rate (eGFR), serum potassium, nutritional markers, and other relevant biochemical parameters. Quality of life and dietary adherence will be evaluated through questionnaires and food frequency records. This study will evaluate primarily, the feasibility of a plant-based diet in the Singaporean context. Secondarily it will evaluate its safety in terms of incidence of hyperkalaemia, and benefit in terms of improvement in acidosis. Other exploratory outcomes will include (1) preliminary efficacy of plant-based diets on CKD progression (measured by eGFR decline); (2) risk of nutritional deficiencies such as vitamin D, B12 and iron; and (3) impact on other biochemical parameters of CKD.
CONDITIONS
Official Title
Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 21 to 79 years and able to give consent
- Diagnosed with Stage 3 or 4 chronic kidney disease (eGFR 15-60 ml/min/1.72m2 for past 6 months)
- Willing to see a dietitian and follow either a standard CKD diet or a predominantly plant-based CKD diet
- On maximum tolerated dose of ACE-inhibitors or ARB as determined by renal physician
- Able to provide informed consent
You will not qualify if you...
- Kidney transplant patients
- Pregnant or lactating patients
- Patients on any special diet for at least 1 month prior to recruitment, including long-term vegans or vegetarians
- Age under 21 or 80 and above
- Patients who have previously seen a dietitian for CKD
- Patients with severe ischemic heart disease, decompensated liver cirrhosis, malabsorptive diseases, or malignancy
- Patients with BMI under 18.5 or over 40
- Patients with glomerulonephritis, genetic kidney disease, or polycystic kidney disease
- Baseline serum potassium 5.0 or above
- Patients unable to modify their diet due to socio-economic issues
- Patients with acute kidney injury in the past 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Changi General Hospital
Singapore, Singapore, 529889
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here